In:
International Journal of Cancer, Wiley, Vol. 120, No. 10 ( 2007-05-15), p. 2191-2195
Abstract:
Accumulating evidence implicates epigenetic changes such as hypermethylation in carcinogenesis. We investigated whether DNA methylation of 5 tumor suppressor genes in pleural fluid samples could aid in diagnosis of malignant effusion. In samples from 47 patients with malignant pleural effusions and 34 with nonmalignant effusions, we used a methylation‐specific polymerase chain reaction to detect aberrant hypermethylation of the promoters of the DNA repair gene O 6 ‐methylguanine‐DNA methyltransferase ( MGMT ), p16 INK4a , ras association domain family 1A ( RASSF1A ), apoptosis‐related genes, death‐associated protein kinase ( DAPK ), and retinoic acid receptor β ( RAR β). Promoter hypermethylation was associated with malignant effusion for MGMT (Odds ratio (OR) = ∞), p16 INK4a (OR = ∞), RASSF1A (OR = 13.8; CI, 1.71–112), and RAR β (OR = 3.17; CI, 1.10–9.11), but not for DAPK . Instead, DAPK methylation was associated with the length of smoking ( p 〈 0.05). Patients with hypermethylation of MGMT , p16 INK4a , RASSF1A or RAR β were 5.68 times more likely to have malignant effusions than patients without methylation ( p = 0.008). Methylations per patient were more numerous for lung cancer than nonmalignant pulmonary disease (0.915 vs . 0.206, p 〈 0.001). Sensitivity, specificity, and positive predictive value of methylation in one or more genes for diagnosis of malignant effusion were 59.6%, 79.4%, and 80.0% respectively. In conclusion, aberrant promoter methylation of tumor suppressor genes in pleural fluid DNA could be a valuable diagnostic marker for malignant pleural effusion. © 2007 Wiley‐Liss, Inc.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2007
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink